Header Logo

Connection

JOHN KIRKWOOD to Chemotherapy, Adjuvant

Back to Details
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Chemotherapy, Adjuvant.
JOHN KIRKWOOD
Connection Strength
3.955
Chemotherapy, Adjuvant
  1. Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors. Cancer Treat Rev. 2013 Feb; 39(1):27-43.
    View in: PubMed
    Score: 0.365
  2. Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med. 2008 Oct 27; 6:62.
    View in: PubMed
    Score: 0.287
  3. Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma. Nat Clin Pract Oncol. 2008 Jan; 5(1):2-3.
    View in: PubMed
    Score: 0.269
  4. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004 Mar 01; 10(5):1670-7.
    View in: PubMed
    Score: 0.208
  5. Adjuvant high-dose interferon-alpha therapy for high-risk melanoma. Forum (Genova). 2003; 13(2):127-40; quiz 187-8.
    View in: PubMed
    Score: 0.192
  6. Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609. J Clin Oncol. 2020 02 20; 38(6):567-575.
    View in: PubMed
    Score: 0.156
  7. An updated analysis of 4 randomized ECOG trials of high-dose interferon in the adjuvant treatment of melanoma. Cancer. 2019 09 01; 125(17):3013-3024.
    View in: PubMed
    Score: 0.149
  8. Adjuvant Therapy in Resected Melanoma. N Engl J Med. 2018 02 15; 378(7):679-680.
    View in: PubMed
    Score: 0.137
  9. Phase III Randomized Study of 4 Weeks of High-Dose Interferon-a-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697). J Clin Oncol. 2017 Mar 10; 35(8):885-892.
    View in: PubMed
    Score: 0.127
  10. Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma. J Transl Med. 2015 Sep 30; 13:319.
    View in: PubMed
    Score: 0.116
  11. Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa. Melanoma Res. 2014 Apr; 24(2):150-7.
    View in: PubMed
    Score: 0.104
  12. Advances in adjuvant therapy: potential for prognostic and predictive biomarkers. Methods Mol Biol. 2014; 1102:45-69.
    View in: PubMed
    Score: 0.103
  13. Neoadjuvant therapy for high-risk bulky regional melanoma. J Surg Oncol. 2011 Sep; 104(4):386-90.
    View in: PubMed
    Score: 0.087
  14. Melanoma in pediatric, adolescent, and young adult patients. Semin Oncol. 2009 Oct; 36(5):419-31.
    View in: PubMed
    Score: 0.076
  15. Response to "helping melanoma patients decide whether to choose adjuvant high-dose interferon-alpha2b". Oncologist. 2006 May; 11(5):538-9; author reply 539-40.
    View in: PubMed
    Score: 0.060
  16. Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 2):2331s-2336s.
    View in: PubMed
    Score: 0.060
  17. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006 Feb 16; 354(7):709-18.
    View in: PubMed
    Score: 0.060
  18. Building upon the standard of care in adjuvant therapy of high-risk melanoma. J Clin Oncol. 2005 Dec 01; 23(34):8559-63.
    View in: PubMed
    Score: 0.058
  19. Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med. 2024 Nov 07; 391(18):1709-1720.
    View in: PubMed
    Score: 0.053
  20. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group. Cancer. 2004 Apr 15; 100(8):1692-8.
    View in: PubMed
    Score: 0.052
  21. Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study. J Clin Oncol. 2024 May 10; 42(14):1619-1624.
    View in: PubMed
    Score: 0.052
  22. Medical management of melanoma. Surg Clin North Am. 2003 Apr; 83(2):283-322, viii.
    View in: PubMed
    Score: 0.049
  23. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med. 2023 03 02; 388(9):813-823.
    View in: PubMed
    Score: 0.048
  24. Adjuvant therapy of melanoma. Semin Cutan Med Surg. 2003 Mar; 22(1):55-67.
    View in: PubMed
    Score: 0.048
  25. Sentinel lymph node biopsy and adjuvant therapy for melanoma: evidence revisited. Arch Dermatol. 2003 Jan; 139(1):99; author reply 99-100.
    View in: PubMed
    Score: 0.048
  26. Use and abuse of statistics in evidence-based medicine. J Clin Oncol. 2002 Oct 01; 20(19):4122-3; author reply 4123-4.
    View in: PubMed
    Score: 0.047
  27. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol. 2002 Sep 01; 20(17):3703-18.
    View in: PubMed
    Score: 0.047
  28. Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690. Cancer. 2002 Sep 01; 95(5):1101-12.
    View in: PubMed
    Score: 0.047
  29. Update on adjuvant interferon therapy for high-risk melanoma. Oncology (Williston Park). 2002 Sep; 16(9):1177-87; discussion 1190-2, 1197.
    View in: PubMed
    Score: 0.047
  30. Differential effect of IFNalpha-2b on the cytochrome P450 enzyme system: a potential basis of IFN toxicity and its modulation by other drugs. Clin Cancer Res. 2002 Aug; 8(8):2480-7.
    View in: PubMed
    Score: 0.047
  31. Interferon alfa-2a for melanoma metastases. Lancet. 2002 Mar 16; 359(9310):978-9.
    View in: PubMed
    Score: 0.045
  32. Developing indications for the use of sentinel lymph node biopsy and adjuvant high-dose interferon alfa-2b in melanoma. Arch Dermatol. 2001 Sep; 137(9):1217-24.
    View in: PubMed
    Score: 0.044
  33. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol. 2001 Mar 01; 19(5):1430-6.
    View in: PubMed
    Score: 0.042
  34. Update on the role of adjuvant interferon for high risk melanoma. Forum (Genova). 2000 Jul-Sep; 10(3):230-9.
    View in: PubMed
    Score: 0.040
  35. Adjuvant interferon in the treatment of melanoma. Br J Cancer. 2000 May; 82(10):1755-6.
    View in: PubMed
    Score: 0.040
  36. KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncol. 2020 Jan; 16(3):4429-4438.
    View in: PubMed
    Score: 0.039
  37. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 05; 20(5):701-710.
    View in: PubMed
    Score: 0.037
  38. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2018 07; 19(7):916-929.
    View in: PubMed
    Score: 0.035
  39. Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy. J Natl Cancer Inst. 2018 01 01; 110(1).
    View in: PubMed
    Score: 0.034
  40. Economic analyses of benefit from interferon-alpha 2B in high-risk melanoma: trade-offs between completeness, simplicity and clarity. Eur J Cancer. 1997 Aug; 33(9):1345-6.
    View in: PubMed
    Score: 0.033
  41. Adjuvant interferon-a for the treatment of high-risk melanoma: An individual patient data meta-analysis. Eur J Cancer. 2017 09; 82:171-183.
    View in: PubMed
    Score: 0.033
  42. Interferon adjuvant therapy of melanoma. Cancer. 1997 May 01; 79(9):1843-6.
    View in: PubMed
    Score: 0.032
  43. Efficacy, safety, and risk-benefit analysis of adjuvant interferon alfa-2b in melanoma. Semin Oncol. 1997 Feb; 24(1 Suppl 4):S16-23.
    View in: PubMed
    Score: 0.032
  44. Adjuvant application of interferons. Semin Oncol. 1996 Dec; 23(6):737-43.
    View in: PubMed
    Score: 0.031
  45. Interferons in melanoma. Curr Opin Oncol. 1996 Mar; 8(2):167-74.
    View in: PubMed
    Score: 0.030
  46. Potential uses of interferon alpha 2 as adjuvant therapy in cancer. Ann Surg Oncol. 1995 Jul; 2(4):365-71.
    View in: PubMed
    Score: 0.028
  47. A new mathematical model for the interpretation of translational research evaluating six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon. PLoS One. 2014; 9(1):e86375.
    View in: PubMed
    Score: 0.026
  48. A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon. PLoS One. 2012; 7(7):e40805.
    View in: PubMed
    Score: 0.023
  49. Studies of interferons in the therapy of melanoma. Semin Oncol. 1991 Oct; 18(5 Suppl 7):83-90.
    View in: PubMed
    Score: 0.022
  50. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist. 2011; 16(1):5-24.
    View in: PubMed
    Score: 0.021
  51. Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon. Cancer. 2010 Sep 15; 116(18):4326-33.
    View in: PubMed
    Score: 0.020
  52. Meeting report from the Third Global Workshop on Melanoma. Pigment Cell Melanoma Res. 2010 Oct; 23(5):e1-7.
    View in: PubMed
    Score: 0.020
  53. Update: current management issues in malignant melanoma. Melanoma Res. 2005 Oct; 15(5):319-24.
    View in: PubMed
    Score: 0.014
  54. Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b. J Clin Oncol. 2004 Jan 01; 22(1):11-4.
    View in: PubMed
    Score: 0.013
  55. Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data. J Clin Oncol. 2002 Mar 01; 20(5):1311-8.
    View in: PubMed
    Score: 0.011
  56. Patient preferences for adjuvant interferon alfa-2b treatment. J Clin Oncol. 2001 Feb 01; 19(3):812-23.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.